06118 AUSTAR
- 0.920
- +0.020+2.22%
AUSTAR News
Agency: The synthetic biology sector showed a high increase in Q1 performance, and policy expectations accelerated valuation repair
Currently, the core competitiveness of biological manufacturing companies lies in product development and implementation capabilities. They are optimistic about targets with successful cases, leading positions, high-quality product reserves, and a boom in downstream demand.
奧星生命科技：2023年報
Aoxing Life Technology (06118.HK)'s total annual revenue was about 1,764 billion yuan, a year-on-year decrease of about 18.2%
Gelonghui, March 26, 丨 Aoxing Life Technology (06118.HK) announced that for the year ended December 31, 2023, the Group's total revenue was approximately RMB 1,763.7 million, a decrease of about 18.2% compared to the year ended December 31, 2022. This was mainly due to reduced revenue from the Fluid and Bioprocess Systems, Clean Room and Automated Control and Monitoring Systems and Life Science Consumables business segments, partially offset by increased revenue from the Powder Solids Systems, Pharmaceutical Equipment Distribution and Agency business segments. The Group recorded an annual loss of RMB 151.3 million in the current year compared to 2
Aoxing Life Technology (06118) announced the 2023 annual results. Shareholders' share loss of 113 million yuan changed from profit to loss year-on-year
According to the Zhitong Finance App, Aoxing Life Technology (06118) disclosed its 2023 annual results. The group achieved revenue of 1,764 billion yuan (RMB, same below) during the reporting period, a year-on-year decrease of 18.23%. Gross profit of 336 million yuan, a year-on-year decrease of 31.25%. The owners of the company should have accounted for a loss of 113 million yuan during the year, changing from profit to loss over the same period last year. Loss of $0.22 per share. During the reporting period, the group's order volume decreased by about 32.7% compared to 2022, due to a decrease in the number of projects and delays in project progress due to a slowdown in capital expenditure investment after recovering from the COVID-19 pandemic.
AUSTAR: ANNOUNCEMENT OF ANNUAL RESULTS FOR THE YEAR ENDED 31 DECEMBER 2023
Aoxing Life Technology (06118.HK) held a board meeting on March 26 to consider and approve annual results
Glonghui March 14 | Aoxing Life Technology (06118.HK) announced that the board of directors meeting will be held on March 26, 2024 (Tuesday) to consider and approve (including) the Group's annual results for the year ended 31 December 2023 and the proposed payment of a final dividend (if any).
奧星生命科技：董事會會議通告
A major favorable raid, and the 1.6 trillion innovative drug sector is booming!
The advantage suddenly “smashed” into the pharmaceutical sector!
Investors Give Austar Lifesciences Limited (HKG:6118) Shares A 27% Hiding
Austar Lifesciences Limited (HKG:6118) shares have had a horrible month, losing 27% after a relatively good period beforehand.
A quick overview of the Hong Kong market | The Hang Seng Index rose nearly 2%, and the Science Index rose nearly 3%; insurance, real estate and other sectors were strong throughout the day
Technet stocks were strong. Meituan rose nearly 5%, Bilibili and Kuaishou rose more than 3%, Xiaomi and Jingdong rose more than 2%, Baidu, Ali, and Tencent rose more than 1%, and NetEase followed; insurance stocks were strong throughout the day. China Ping An rose more than 6%, China Life Insurance rose nearly 5%, and AIA Insurance rose more than 2%.
Intraday Overview | The three major indices rose slightly, and the Tech Index rose nearly 2%; auto stocks and biotech stocks rose strongly. NIO rose nearly 8%, and Pharmaceutical Biotech rose more than 9%
Most Technology Network stocks rose, with Station B up more than 4%; Meituan and NetEase up more than 3%; mobile phone equipment stocks showed active performance, with Shunyu Optical Technology up more than 7% and Gaowei Electronics by more than 5%; pharmaceutical distribution stocks improved, Ali Health rose more than 8%, and JD Health rose nearly 5%.
Intraday Overview | The Tech Index fell more than 2%, Apple concept stocks and pharmaceutical stocks had the highest declines, and Shunyu Optical Technology fell more than 8%
Technet stocks collectively weakened, with Xiaomi falling nearly 4%, Meituan falling nearly 3%, and Kuaishou falling more than 2%; domestic housing stocks continued to decline, with Country Garden falling more than 3%; Longhu Group, Xincheng Development, and Sunac China falling nearly 2%; auto stocks were weak, with Zero Sports Auto and NIO falling more than 5%, and Xiaopeng Motors falling more than 4%.
Austar Lifesciences to Swing to Loss; Shares Drop
Shares of Austar Lifesciences (HKG:6118) dropped some 8% in recent trade after the firm said it expects an attributable loss of about 110 million yuan for the fiscal year through December 2023, as com
Selected Announcements | China Merchants Bank's net profit last year exceeded 146.6 billion yuan; China Telecom's 5G users increased by 50.7 million last year
Haifeng International issued a profit warning. The profit due to shareholders in 2023 is expected to be about 530 million US dollars, down about 73% from the previous year; Zero Sports Auto will issue H shares and domestic shares to raise up to 600 million yuan.
Aoxing Life Technology (06118.HK) Profit Alert: Expected annual loss of about 110 million yuan
Gelonghui, January 19, 丨 Aoxing Life Technology (06118.HK) announced that the company expects to record a loss attributable to the company owner of about RMB 110 million for the year ended December 31, 2023, compared to the profit attributable to the company owner of approximately RMB 87 million for the year ended December 31, 2022. Expected losses are mainly due to: (1) In the 2023 fiscal year, H+E Pharma GmbH and S-tec GmbH (the company's then indirect non-wholly-owned subsidiary) filed for bankruptcy on August 3, 2023
Innovative drugs, the standard-bearer of the Hong Kong stock market
However, the protagonist leading the rebound of A/H shares in this round is innovative pharmaceuticals+consumer electronics. Judging from the past half month, consumer electronics has performed better in A-shares, while innovative drugs have performed more fiercely in Hong Kong stocks.
Austar Lifesciences Hires New Auditor
Austar Lifesciences (HKG:6118) has hired Moore CPA as its auditor effective today, Nov. 17. Moore will fill the casual vacancy arising from the termination of PricewaterhouseCoopers' (PwC) services. E
Intraday quick overview | The three major indices rushed higher and fell, and the index rose slightly; pharmaceutical stocks and domestic housing stocks had the highest gains, Pharmaceuticals Biotech rose more than 5%, and Country Garden rose more than 4%
Most of the Internet of Technology stocks rose, Kuaishou and Tencent rose nearly 2%; most auto stocks fell; Xiaopeng Motor fell by more than 4%, and Zero Sports fell by more than 3%.
Can we expect a large-scale market? Pharmaceutical funds have rebounded across the board. What I'm most concerned about is actually...
What pharmaceutical fund managers are most worried about now is whether non-pharmaceutical funds and top players will think about it again in the midst of a ferocious pharmaceutical backlash.
The Hong Kong Stock Exchange Index fell nearly 6% in the third quarter, but public funds bucked the trend and increased their positions in this sector
① What was the overall position of public funds in the third quarter? ② What do you think of the Hong Kong stock market in the future?
Analysis
Price Target
No Data
